Abstract
Interleukin (IL)-22 belongs to the IL-10 cytokine family which performs biological functions by binding to heterodimer receptors comprising a type 1 receptor chain (R1) and a type 2 receptor chain (R2). IL-22 is mainly derived from CD4+ helper T cells, CD8+ cytotoxic T cells, innate lymphocytes, and natural killer T cells. It can activate downstream signaling pathways such as signal transducer and activator of transcription (STAT)1/3/5, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) through these heterodimer receptors. Although IL-22 is produced by immune cells, its specific receptor IL-22R1 is selectively expressed in nonimmune cells, such as hepatocytes, colonic epithelial cells, and pancreatic epithelial cells (Jiang et al. Hepatology 54(3):900–9, 2011; Jiang et al. BMC Cancer 13:59, 2013; Curd et al. Clin Exp Immunol 168(2):192–9, 2012). Immune cells do not respond to IL-22 stimulation directly within tumors, reports from different groups have revealed that IL-22 can indirectly regulate the tumor microenvironment (TME). In the present chapter, we discuss the roles of IL-22 in malignant cells and immunocytes within the TME, meanwhile, the potential roles of IL-22 as a target for drug discovery will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ouyang W et al (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109
Sheppard P et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68
Kotenko SV (2002) The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 13(3):223–240
Sabat R et al (2007) IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 11(5):601–612
Wolk K, Sabat R (2006) Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 17(5):367–380
Sanos SL et al (2009) RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 10(1):83–91
Takatori H et al (2009) Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206(1):35–41
Brand S et al (2007) IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 292(4):G1019–G1028
Sabat R, Ouyang W, Wolk K (2014) Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13(1):21–38
Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809
Jiang R et al (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54(3):900–909
Jiang R et al (2013) IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 13:59
Curd LM, Favors SE, Gregg RK (2012) Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 168(2):192–199
Nardinocchi L et al (2015) Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol 45(3):922–931
Dudakov JA et al (2012) Interleukin-22 drives endogenous thymic regeneration in mice. Science 336(6077):91–95
Ouyang W, O’Garra A (2019) IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50(4):871–891
Molina MF et al (2019) Type 3 cytokines in liver fibrosis and liver cancer. Cytokine 124:154497
Park O et al (2011) In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 54(1):252–261
Zhao D et al (2015) Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer 136(11):2556–2565
Hwang S et al (2019) Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 72(2):412–429
Rolla S et al (2016) The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clin Sci (Lond) 130(3):193–203
Fukui H et al (2011) DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowel Dis 17(5):1177–1188
Kryczek I et al (2014) IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40(5):772–784
Liu Y et al (2017) Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells. Oncotarget 8(15):25372–25383
Gronke K et al (2019) Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature 566(7743):249–253
Wang C et al (2017) Interleukin-22 drives nitric oxide-dependent DNA damage and dysplasia in a murine model of colitis-associated cancer. Mucosal Immunol 10(6):1504–1517
Lin Y et al (2017) Lactobacillus delivery of bioactive interleukin-22. Microb Cell Factories 16(1):148
Xuan X et al (2018) Diverse effects of interleukin-22 on pancreatic diseases. Pancreatology 18(3):231–237
Xuan X et al (2020) ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling. Clin Transl Oncol 22(4):563–575
Dixon BR et al (2016) IL-17a and IL-22 induce expression of antimicrobials in gastrointestinal epithelial cells and may contribute to epithelial cell defense against helicobacter pylori. PLoS One 11(2):e0148514
Zhuang Y et al (2012) Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother 61(11):1965–1975
Fukui H et al (2014) IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling. Br J Cancer 111(4):763–771
Chen X et al (2018) Accumulation of T-helper 22 cells, interleukin-22 and myeloid-derived suppressor cells promotes gastric cancer progression in elderly patients. Oncol Lett 16(1):253–261
Kobold S et al (2013) Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol 8(8):1032–1042
Zhang W et al (2008) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14(20):6432–6439
Bi Y et al (2016) Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol Cell Biochem 415(1-2):1–11
Naumnik W et al (2016) Clinical implications of hepatocyte growth factor, interleukin-20, and interleukin-22 in serum and bronchoalveolar fluid of patients with non-small cell lung cancer. Adv Exp Med Biol 952:41–49
Voigt C et al (2017) Cancer cells induce interleukin-22 production from memory CD4(+) T cells via interleukin-1 to promote tumor growth. Proc Natl Acad Sci U S A 114(49):12994–12999
Li H et al (2019) Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway. Am J Transl Res 11(7):4077–4088
Katara GK et al (2020) Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer. Mol Oncol 14(1):211–224
Wang S et al (2018) Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways. Biochem Biophys Res Commun 503(3):1605–1609
Rui J et al (2017) IL-22 promotes the progression of breast cancer through regulating HOXB-AS5. Oncotarget 8(61):103601–103612
Weber GF et al (2006) IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177(11):8266–8272
Kim K et al (2014) Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP 3K8 activation. Carcinogenesis 35(6):1352–1361
Bard JD et al (2008) Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 22(8):1595–1603
Prutsch N et al (2019) Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia 33(3):696–709
Kouzegaran S et al (2018) Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia. Cytometry B Clin Cytom 94(1):143–147
Chen P et al (2015) The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia. J Immunol Res 2015:416123
Tian T et al (2013) Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. Clin Chim Acta 426:108–113
Yu S et al (2014) Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia. Int J Mol Sci 15(2):1927–1945
Tian T et al (2015) The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. PLoS One 10(7):e0131761
Jin M, Yoon J (2018) From bench to clinic: the potential of therapeutic targeting of the IL-22 signaling pathway in atopic dermatitis. Immune Netw 18(6):e42
Kragstrup TW et al (2018) The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis. Front Immunol 9:2226
Huber S et al (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491(7423):259–263
Fagard R et al (2013) STAT3 inhibitors for cancer therapy: have all roads been explored? JAKSTAT 2(1):e22882
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jiang, R., Sun, B. (2021). IL-22 Signaling in the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment . Advances in Experimental Medicine and Biology, vol 1290. Springer, Cham. https://doi.org/10.1007/978-3-030-55617-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-55617-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-55616-7
Online ISBN: 978-3-030-55617-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)